FİBROMYALJİ SENDROMUNDA KİNEZYOFOBİ: OBEZİTE, AĞRI ŞİDDETİ, YÜKSEK HASTALIK AKTİVİTESİ İLİŞKİSİ

Amaç: Fibromiyalji sendromunda hastalık şiddeti ile kinezyofobi arasındaki ilişkinin araştırılması amaçlandı.

Anahtar Kelimeler:

Fibromiyalji Sendromu, Kinezyofobi, Tampa Kinezyofobi Ölçeği, Fibromiyalji Etki Anketi, Hareket Korkusu

Kinesiophobia in Fibromyalgia Syndrome: Relationship with Obesity, Pain Intensity, High Disease Activity

Objective: It was aimed to investigate the relationship between disease severity and kinesiophobia in Fibromyalgia Syndrome.

Keywords:

Fiibromialgia Syndrome, Kinesiophobia, Tampa Scale of Kinesiophobia, Fibromialgia Impact Questionnaire, Fear of Movement,

PDF

___

1. Bair MJ, Krebs EE. Fibromyalgia. Ann Intern Med. 2020;172(5):33-48.
2. Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645-60.
3. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017:76(2);318-28.
4. Langhorst J, Heldmann P, Henningsen P, Kopke K, Krumbein L, Lucius H et al. Complementary and alternative procedures for fibromyalgia syndrome: Updated guidelines 2017 and overview of systematic review articles. Schmerz. 2017;31(3):289-95.
5. Schiltenwolf M, Eidmann U, Köllner V, Kühn T, Offenbächer M, Petzke F et al. Multimodal therapy of fibromyalgia syndrome: Updated guidelines 2017 and overview of systematic review articles. Schmerz. 2017;31(3):285-8.
6. Damas PR, Marín BF, Sánchez MF, Larrea VP. Fibromyalgia syndrome and fear. Aten Primaria. 2021;53(9):102137.
7. Andrade A, Torres Vilarino G, Mendes Sieczkowska S, Reis Coimbra D, Klumb Steffens RA, Grunewald Vietta G. Acute effects of physical exercises on the inflammatory markers of patients with fibromyalgia syndrome: A systematic review. J Neuroimmunol. 2018;316:40-9.
8. Kori SH, Miller RP, Todd DD. Kinesiophobia: A new view of chronic pain behavior. Pain Manage 1990;3:35-43.
9. Russek L, Gardner S, Maguire K, Stevens C, Brown EZ, Jayawardana V et al. A cross-sectional survey assessing sources of movement-related fear among people with fibromyalgia syndrome. Clin Rheumatol. 2015;34(6):1109-19.
10. Varallo G, Scarpina F, Giusti EM, Cattivelli R, Usubini AG, Capodaglio P et al. Does kinesiophobia mediate the relationship between pain intensity and disability in individuals with chronic low-back pain and obesity? Brain Sci. 2021;11(6):684.
11. Wolfe F, Walitt BT, Katz RS, Häuser W. Social security work disability and its predictors in patients with fibromyalgia. Arthritis Care Res. 2014;66(9):1354-63.
12. Turk DC, Robinson JP, Burwinkle T. Prevalence of fear of pain and activity in patients with fibromyalgia syndrome. J Pain. 2004;5(9):483-90.
13. Leeuw M, Goossens ME, Linton SJ, Crombez G, Boersma K, Vlaeyen JW. The fear-avoidance model of musculoskeletal pain: current state of scientific evidence. J Behav Med. 2007;30(1):77-94.
14. Koçyiğit BF, Akaltun MS. kinesiophobia levels in fibromyalgia syndrome and the relationship between pain, disease activity, depression. Arch Rheumatol. 2020;35(2):214-9.
15. Jiménez-Cebrián AM, Becerro-de-Bengoa-Vallejo R, Losa-Iglesias ME, de Labra C, Calvo-Lobo C, Palomo-López P et al. Kinesiophobia levels in patients with parkinson's disease: a case-control investigation. Int J Environ Res Public Health. 2021;18(9):4791.
16. Wasiuk-Zowada D, Knapik A, Szefler-Derela J, Brzęk A, Krzystanek E. kinesiophobia in stroke patients, multiple sclerosis and parkinson's disesase. Diagnostics (Basel). 2021;11(5):796.
17. Lundberg M, Styf J, Jansson B. On what patients does the Tampa Scale for Kinesiophobia fit? Physiother Theory Pract. 2009;25(7):495-506.
18. Yilmaz ÖT, Yakut Y, Uygur F, Uluğ N. Tampa Kinezyofobi Ölçeği’nin Türkçe versiyonu ve test-tekrar test güvenirliği. Fizyoterapi Rehabilitasyon. 2011;22(1),44-9.
19. Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol. 2005;23(5):154-62.
20. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int. 2000;20(1):9-12.
21. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. 2011;63 (11):240-52.
22. Velasco L, López-Gómez I, Gutiérrez L, Écija C, Catalá P, Peñacoba C. Exploring the preference for fatigue-avoidance goals as a mediator between pain catastrophizing, functional impairment, and walking behavior in women with fibromyalgia. Clin J Pain. 2021;38(3):182-8.
23. Vincent HK, Omli, MR, Day T, Hodges M, Vincent KR, George SZ. Fear of movement, quality of life, and self-reported disability in obese patients with chronic lumbar pain. Pain Med. 2011;12(1):154-64.
24. Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. Pain. 2000;85(3):317-32.
25. Varallo G, Scarpina F, Giusti EM, Suso-Ribera C, Cattivelli R, Guerrini Usubini A et al. The role of pain catastrophizing and pain acceptance in performance-based and self-reported physical functioning in individuals with fibromyalgia and obesity. J Pers Med. 2021;11(8):810.
26. Okifuji A, Donaldson GW, Barck L, Fin, PG. Relationship between fibromyalgia and obesity in pain, function, mood, and sleep. J Pain. 2010;11(12):1329-37.
27. Burwinkle T, Robinson JP, Turk DC. Fear of movement: factor structure of the tampa scale of kinesiophobia in patients with fibromyalgia syndrome. J Pain. 2005;6(6):384-91.
28. Turk DC, Okifuji A, Starz TW, Sinclair JD. Effects of type of symptom onset on psychological distress and disability in fibromyalgia syndrome patients. Pain. 1996;68(2-3):423-30.